Stathmin 1: A protein with many tasks. New biomarker and potential target in cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 7, 2012, Pages 631-634

  Nemunaitis, John ^a,b,c  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

biomarker; cancer; cancer therapy; stathmin 1

Indexed keywords

ALPHA TUBULIN; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA TUBULIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PROTEASOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN C JUN; PROTEIN FOXM1; PROTEIN P27; PROTEIN P53; PUMA PROTEIN; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STATHMIN; STATHMIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR E2F; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRESS; COLORECTAL CANCER; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; LYMPH NODE METASTASIS; MICROTUBULE ASSEMBLY; PROGNOSIS; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

HUMANS; NEOPLASMS; STATHMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862545032     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.696101     Document Type: Review

References (38)

1. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011;15(11):1249-66
2. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002;14(1):18-24 (Pubitemid 34131652)
3. Wang F, Wang LX, Li SL, et al. Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma. J Surg Oncol 2011;103(7):704-15
4. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 2005;4(12):1821-9 (Pubitemid 43056965)
5. Niethammer P, Kronja I, Kandels-Lewis S, et al. Discrete states of a protein interaction network govern interphase and mitotic microtubule dynamics. PLoS Biol 2007;5(2):e29
6. Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin prevents the transition from a normal to an endomitotic cell cycle during megakaryocytic differentiation. Cell Cycle (Georgetown, Tex) 2005;4(12):1774-82 (Pubitemid 41827324)
7. Gavet O, Ozon S, Manceau V, et al. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J Cell Sci 1998;111(Pt 22):3333-46 Demonstrates effect on microtubules. (Pubitemid 28563036)
8. Manna T, Thrower D, Miller HP, et al. Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J Biol Chem 2006;281(4):2071-8 (Pubitemid 43845795)
9. Holmfeldt P, Sellin ME, Gullberg M. Upregulated Op18/stathmin activity causes chromosomal instability through a mechanism that evades the spindle assembly checkpoint. Exp Cell Res 2010;316(12):2017-26
10. Baldassarre G, Belletti B, Nicoloso MS, et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7(1):51-63 (Pubitemid 40126382)
11. Jeon TY, Han ME, Lee YW, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010;102(4):710-18 Demonstrates relationship of STMN1 in cancer.
12. Zheng P, Liu YX, Chen L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010;9(10):4897-905
13. Nemunaitis J, Senzer N, Khalil I, et al. Proof concept for clinical justification of network mapping for personalized cancer therapeutics. Cancer Gene Ther 2007;14(8):686-95 (Pubitemid 47080360)
14. Shen Y SN, Nemunaitis J. Use of proteomics analysis for molecular precision approaches in cancer therapy. Drug Target Insights 2008;3:12
15. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008;8(9):1461-70 Shows potential of STMN1 knockdown as therapy in cancer.
16. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007;26(7):1003-12
17. Nishio K, Nakamura T, Koh Y, et al. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 2001;91(8):1494-9 (Pubitemid 32319260)
18. Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011;17(10):3368-77
19. Carr JR, Park HJ, Wang Z, et al. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010;70(12):5054-63
20. Ahn J, Murphy M, Kratowicz S, et al. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999;18(43):5954-8 (Pubitemid 29520452)
21. Fang L, Min L, Lin Y, et al. Downregulation of stathmin expression is mediated directly by Egr1 and associated with p53 activity in lung cancer cell line A549. Cell Signal 2010;22(1):166-73
22. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7(3):683-94 (Pubitemid 32706359)
23. Belletti B, Nicoloso MS, Schiappacassi M, et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008;19(5):2003-13 Shows functional role of STMN1 in cancer.
24. Schiappacassi M, Lovisa S, Lovat F, et al. Role of T198 modification in the regulation of p27(Kip1) protein stability and function. PLoS One 2011;6(3):e17673
25. Verma NK, Dourlat J, Davies AM, et al. STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. J Biol Chem 2009;284(18):12349-62
26. Wang X, Ren JH, Lin F, et al. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther 2010;10(6):632-43
27. Jiang L, Chen Y, Chan CY, et al. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 2009;274(1):101-8
28. Su D, Smith SM, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009;115(11):2453-63 Shows relation of STMN1 and chemotherapy.
29. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001;11(1):41-9 Shows effect of STMN1 knockdown to mitosis. (Pubitemid 32199393)
30. Zhang HZ, Wang Y, Gao P, et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumorcells. Cancer Biol Ther 2006;5(11):1457-61 Shows effect of STMN1 knockdown in cancer.
31. Wang R, Dong K, Lin F, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med (Cambridge, Mass) 2007;13(11-12):567-75 Shows effect of taxanes and RNAi in cancer. (Pubitemid 350228717)
32. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther 2006;5(12):3248-57 (Pubitemid 46092068)
33. Ngo TT, Peng T, Liang XJ, et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007;99(8):639-52 (Pubitemid 47073545)
34. Iancu C, Mistry SJ, Arkin S, et al. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001;114(Pt 5):909-16 Shows role of STMN1 to mitotic spindle function. (Pubitemid 32266262)
35. Longuet M, Serduc R, Riva C. Implication of bax in apoptosis depends on microtubule network mobility. Int J Oncol 2004;25(2):309-17
36. Singer S, Ehemann V, Brauckhoff A, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (Baltimore, Md) 2007;46(3):759-68 (Pubitemid 47436122)
37. Rao DD, Maples PB, Senzer N, et al. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther 2010;17(11):780-91 Demonstrates bi-shRNAi STMN1 product knockdown.
38. Phadke AP, Jay CM, Wang Z, et al. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human stathmin 1 oncoprotein. DNA Cell Biol 2011;30(9):715-26 Shows effect of bi-shRNAi STMN1 lipoplex in cancer models.